The World Health Organization has reported the incidence rate of mantle cell lymphoma globally as 0.5 cases per 100,000 people. Mantle cell lymphoma possess an aggressive disease etiology that usually commences with the enlargement of lymph node and progress to metastasis to other organs such as bone marrow, gastrointestinal tract, and liver.
Patient monitoring devices studied for the scope of the report consists of various products and applications. Rising prevalence of chronic diseases such as cardiovascular diseases, diabetes and obesity, increasing number of geriatric population suffering with respiratory diseases. Increasing number of surgical procedures performed and rising inclination towards healthcare monitoring devices and apps to maintain healthy lifestyle has resulted in the deep market penetration for the patient monitoring devices.
Surgical mesh is a medical device constructed by using synthetic materials or animal tissue and used to provide extra support to weak or damaged tissue. Surgical polypropylene mesh widely adopted in the market due to its stability, durability, low infection risk and high mechanical strength.
The development of capsule endoscopy in 2001 has given gastroenterologists the opportunity to examine the gastrointestinal tract in a non-invasive manner. Capsule endoscopy is a digital healthcare technology that can be utilized to detect gastrointestinal disorders such as gastroparesis, esophageal disease, gastrointestinal bleeding, and colon related diseases, followed by Crohn’s disease and polyposis syndrome. Capsule endoscopy has revolutionized the diagnosis of various parts of the GI system in a very simple manner. Medical professional can gain edge in observing the various parameters of gastrointestinal tract such as temperature, pressure, and pH with the help of capsule endoscopes.
Sterile injectables market is rising with growing demand for biologics in order to treat numerous medical conditions with immediate and effective outcomes. Widening application of injectables have transformed medical treatments as higher quality of sterile injectables have lowered chances of risk or any contamination.
Cryoablation procedure, a minimally invasive procedure performed to destroy cells by deploying cold temperature. It is very well-known technology for efficient destruction of cells while keeping surrounding tissues intact. This fast, cost-effective solution is gaining popularity especially in medical oncology and cardiology area majorly due to lesser side-effects rather than conventional approaches.
Vaccines plays a significant role in prevention and control of different forms of infectious diseases. In the previous years, killed or attenuated vaccines were used, while gradually transitioning to recombinant subunit approach in the last two decades.
The report titled “Wearable Injector Devices Market: Growth, Future Prospects, and Competitive Analysis, 2021 -2029” offers strategic insights into the overall wearable injector devices market along with the market size and estimates for the duration 2019 to 2029.
Growing prevalence of chronic diseases, particularly in the geriatric population, significant advancement in lasers in terms of safety and outcomes, growing demand for cosmetic interventions and minimally invasive ophthalmic procedures are the major drivers of the global surgical lasers market. The advent and surge in demand for non-invasive and minimally invasive surgeries has been a key attribute supporting the growth of this market.
The photopheresis products market is expected to grow at a compound annual growth rate of 6% during the forecast period.The market for photopheresis products is projected to expand as the incidence of autoimmune disorders and the number of organ transplants rise. Photopheresis is a medical treatment that separates white blood cells using a device. Before the patient receives the blood, such white cells are subjected to an 8-methoxy psoralen therapy, followed by UVA irradiation. These white cells are the root cause of sickness.The US Food and Drug Administration has approved photopheresis, commonly known as extracorporeal photopheresis (ECP), for the treatment of cutaneous T-cell lymphoma.
The oncology drugs market includes pharmaceutical products and advanced therapies used to treat cancer. Major treatment classes include chemotherapy, targeted therapy, immunotherapy, hormonal therapy, monoclonal antibodies, antibody-drug conjugates, cancer vaccines and cell-based treatments. These drugs are used across lung, breast, colorectal, prostate, blood, skin, ovarian, liver and other cancer indications.
The global cancer and oncology drugs market is expected to record strong growth through 2035. One current industry estimate projects the market to increase from approximately USD 214.70 billion in 2026 to USD 554.69 billion by 2035, representing a compound annual growth rate of 11.17%. Growth is supported by targeted treatments, developments in proteomics and continued demand for more effective cancer therapies.
The increasing global incidence of cancer is a major market driver. Population ageing, tobacco use, obesity, environmental exposure and lifestyle-related risk factors are contributing to a growing patient population. Improved screening and diagnostic technologies are also identifying more patients at earlier stages, increasing the number of individuals eligible for pharmaceutical treatment.
Targeted therapies represent an important market segment. These drugs act on specific genes, proteins or pathways involved in tumour development. Biomarker testing and companion diagnostics help physicians identify patients who are more likely to respond to particular treatments. Precision oncology is therefore increasing the connection between diagnostic testing and drug selection.
Immunotherapy continues to change cancer treatment by helping the immune system identify and attack tumour cells. Immune checkpoint inhibitors, CAR-T cell therapies and cancer vaccines are being studied across multiple solid and blood cancers. Combination therapies using immunotherapy with chemotherapy, targeted drugs or radiation are also expanding as companies seek to improve treatment response and patient survival.
Other major trends include antibody-drug conjugates, bispecific antibodies, radiopharmaceuticals and personalized cancer vaccines. Artificial intelligence is being used for target identification, molecule screening, clinical-trial planning and analysis of patient data. Biosimilars are gaining importance as patents expire for established oncology biologics, potentially improving access and increasing price competition.
Market expansion may be restrained by high treatment costs, adverse effects and unequal access to cancer care. Oncology drugs require extensive clinical testing, and unsuccessful trials can result in substantial development losses. Drug resistance may reduce long-term treatment effectiveness and create demand for additional therapies. Reimbursement restrictions and complex regulatory requirements can also delay patient access.
North America remains a major market due to high cancer treatment expenditure, research activity and access to new medicines. Europe maintains a significant position, while Asia-Pacific is expected to record strong growth as cancer incidence, healthcare investment and access to treatment increase.
Acute Market Reports provides oncology drugs market research covering drug classes, cancer indications, routes of administration, distribution channels, development pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, biotechnology firms, investors and healthcare organizations assess market demand and growth prospects through 2035.